^
    Back
    Association details:
    Biomarker:BRIP1 mutation
    Cancer:Pancreatic Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    veliparib (ABT-888) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR-I 2020
    Title:

    Abstract CT157: Phase IB study of nivolumab and veliparib in patients with advanced solid tumors and lymphoma with and without alterations in selected DNA repair genes

    Published date:
    04/27/2020
    Excerpt:
    Of note, a patient with pancreatic cancer harboring BRIP1 mutation received 12 cycles of treatment (24 weeks) without disease progression. PFS and OS were 9.0 and 26.8 weeks, respectively.
    DOI:
    10.1158/1538-7445.AM2020-CT157